Page 72 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 3
Supplemental Table 2 PFS/EFS definitions.
First author (year)
Fan et al (2017)34
Kim et al (2017)35
De Oliveira Costa et al (2016)36
Kong et al (2016)37
Mikhaeel et al (2016)38
Mamot et al (2015)39
Zhang et al (2015)40
Carr et al (2014)41
Dabaja et al (2014)42
Mylam et al (2014)43
Nols et al (2014)44
Fuertes et al (2013)45
Gonzalez-Barca et al (2013)46
Itti et al (2013)47
Lanic et al (2012)48
Pregno et al (2012)49
Safar et al (2012)50
Cashen et al (2011)51
Zinzani et al (2011)52
Zhao et al (2007)53
PFS/EFS; definition
PFS; was calculated from the date of acquisition of biopsy results to disease progression, relapse, death of patients from any causes, or the date of last follow-up for surviving ones.
PFS; was calculated from the start of the treatment to disease progression, recurrence or death.
PFS; was defined as the time from the date of diagnosis to the date of disease progression, relapse, or death as a result of any cause or last patient follow-up.
PFS; was defined as the interval between the date of diagnosis and the date of lymphoma progression, first relapse, death from any cause, or the last follow-up date.
PFS; defined as the time from diagnosis to the point of progression or death from any cause. Patients still alive were censored at the date of last contact.
EFS; The primary end point was 2-year EFS from start of treatment. Patients who progressed, relapsed, switched to other treatments (including concomitant radiotherapy), refused to continue trial treatment, or died within 2 years were considered to have treatment failure.
PFS; was defined as the time from the start of treatment to the progression of lymphoma, death from any cause, or last follow-up.
EFS; Study events were relapse after complete remission; death from any cause; treatment escalation for progressive disease while on treatment, and disease progression or failure to achieve complete remission at end-chemotherapy based on the revised response criteria for PET, with confirmation by biopsy that residual or increased 18F-FDG uptake was due to lymphoma. Cases lost to follow-up were censored at date of last known disease status. Date of first treatment as origin.
PFS; was defined as the time from diagnosis until objective tumor progression or death.
PFS; was defined as the time from diagnosis to DLBCL progression or death from any cause. Patients who were still alive at the end of the study were censored at the date of data collection.
PFS; was defined as the time from study entry until disease progression or death due to any cause.
PFS; was defined as the interval from the start of treatment until disease progression of DLBCL, death from any cause or the most recent follow-up.
EFS; An event was defined as follows: nonachievement of a CR or Cru with treatment, relapse after achievement of complete remission, or death from any cause, whichever came first.
PFS; calculated from the date of diagnosis until relapse with censoring at the time of last follow-up.
PFS; was calculated from the date of enrollment until disease progression, relapse or death (from any cause) or last patient follow-up.
PFS; was defined as the time from the start of treatment to death/progression as a result of any cause; patients still alive were censored at the date of last contact.
PFS; was calculated from the date of enrollment until disease relapse, with censoring at the time of last follow-up.
PFS; defined to be the time interval from enrollment in the study to date of relapse.
EFS; was defined as the interval from the date of enrollment to the first evidence of progression, disease relapse, death from any cause, treatment discontinuation due to any adverse event, or patient withdrawal.
PFS; was defined as the time from diagnosis to first evidence of progression or relapse, or to disease related death. Data were censored at other causes of death or if the patients were free of progression/relapse at follow-up.
70